Other OTC - Delayed Quote USD

BioCorRx Inc. (BICX)

0.7800 0.0000 (0.00%)
At close: May 14 at 10:42 AM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Lourdes Felix CEO, CFO & Director 250k -- 1968
Mr. Louis Charles Lucido President & Director 60k -- 1948
Dr. George N. Fallieras Medical Consultant -- -- --

BioCorRx Inc.

2390 East Orangewood Avenue
Suite 500
Anaheim, CA 92806
United States
714 462 4880 https://www.biocorrx.com
Sector: 
Healthcare

Description

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program for substance abuse that includes peer recovery support; and distributes UnCraveRx weight loss management program, a medically assisted weight management program. The company is also developing BICX101, an injectable and implantable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

Corporate Governance

BioCorRx Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 12, 2024 - Aug 16, 2024
BioCorRx Inc. Earnings Call